Roche is positioning an emerging oral therapy as a potential new standard of care for patients battling advanced lung cancer, betting on the drug's efficacy to capture significant market share. Simultaneously, AstraZeneca is accelerating plans to seek commercial approval for the lead candidate in its latest portfolio of targeted cancer treatments, aiming to bolster its oncological footprint. In the blood-thinner category, German conglomerate Bayer has secured a critical win in China. The company received authorization to launch Sunharbo, marking the global debut for a novel class of anticoagulants, a move that signals Bayer's intent to revitalize its pharmaceutical pipeline through regional expansion.